The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival

Leukemia

Volumn 27, Issue 2, 2013, Pages 441-450

  Bommert, K S ^a   Effenberger, M ^a   Leich, E ^b   Kuspert M ^c   Murphy, D ^c   Langer, C ^d   Moll, R ^e   Janz, S ^f   Mottok, A ^b   Weissbach, S ^b   Rosenwald, A ^b   Bargou, R ^a   Bommert, K ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MYC PROTEIN; Y BOX BINDING PROTEIN 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENE ACTIVATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RNA TRANSLATION; STAINING; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT MUTATION; POLYRIBOSOMES; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; Y-BOX-BINDING PROTEIN 1;

EID: 84873570632     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.185     Document Type: Article

References (36)

1. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
2. MacDonald GH, Itoh-Lindstrom YTiP. The transcriptional regulatory protein, YB-1, promotes single-stranded regions in the DRA promoter. J Biol Chem 1995; 270: 3527-3533.
3. Homer C, Knight DA, Hananeia L, Sheard P, Risk J, Lasham A et al. Y-box factor YB1 controls p53 apoptotic function. Oncogene 2005; 24: 8314-8325.
4. Rangan VS, Oskouian B, Smith S. Identification of an inverted CCAAT box motif in the fatty-acid synthase gene as an essential element for modification of transcriptional regulation by cAMP. J Biol Chem 1996; 271: 2307-2312.
5. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447-450.
6. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K et al. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001; 7: 3151-3155.
7. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010; 70: 2840-2851.
8. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005; 65: 4078-4087.
9. Chatterjee M, Rancso C, Stuhmer T, Eckstein N, Andrulis M, Gerecke C et al. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008; 111: 3714-3722.
10. Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM et al. Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res 2005; 65: 7644-7652.
11. Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1992; 89: 232-235.
12. Potter M. Neoplastic development in plasma cells. Immunol Rev 2003; 194: 177-195.
13. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, Morse 3rd HC et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002; 99: 1509-1514.
14. Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia 2011; 25: 1026-1035.
15. Skopelitou A, Hadjiyannakis M, Tsenga A, Theocharis S, Alexopoulou V, Kittas C et al. Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases. Anticancer Res 1993; 13: 1091-1095.
16. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
17. Cobbold LC, Wilson LA, Sawicka K, King HA, Kondrashov AV, Spriggs KA et al. Upregulated c-myc expression in multiple myeloma by internal ribosome entry results from increased interactions with and expression of PTB-1 and YB-1. Oncogene 2010; 29: 2884-2891.
18. Chappell SA, LeQuesne JP, Paulin FE, deSchoolmeester ML, Stoneley M, Soutar RL et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation. Oncogene 2000; 19: 4437-4440.
19. Landsman D. RNP-1, an RNA-binding motif is conserved in the DNA-binding cold shock domain. Nucl Acids Res 1992; 20: 2861-2864.
20. Kloks CP, Spronk CA, Lasonder E, Hoffmann A, Vuister GW, Grzesiek S et al. The solution structure and DNA-binding properties of the cold-shock domain of the human Y-box protein YB-1. J Mol Biol 2002; 316: 317-326.
21. Evdokimova V, Ruzanov P, Imataka H, Raught B, Svitkin Y, Ovchinnikov LP et al. The major mRNA-associated protein YB-1 is a potent 5' cap-dependent mRNA stabilizer. EMBO J 2001; 20: 5491-5502.
22. Bader AG, Vogt PK. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene 2008; 27: 1179-1182.
23. Ashizuka M, Fukuda T, Nakamura T, Shirasuna K, Iwai K, Izumi H et al. Novel translational control through an iron-responsive element by interaction of multifunctional protein YB-1 and IRP2. Mol Cell Biol 2002; 22: 6375-6383.
24. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
25. Kunder S, Calzada-Wack J, Holzlwimmer G, Muller J, Kloss C, Howat W et al. A comprehensive antibody panel for immunohistochemical analysis of formalinfixed, paraffin-embedded hematopoietic neoplasms of mice: analysis of mouse specific and human antibodies cross-reactive with murine tissue. Toxicol Pathol 2007; 35: 366-375.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
27. Paulin FE, West MJ, SulliVan NF, Whitney RL, Lyne L, Willis AE. Aberrant translational control of the c-myc gene in multiple myeloma. Oncogene 1996; 13: 505-513.
28. Ponten F, Jirstrom K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008; 216: 387-393.
29. Dong J, Akcakanat A, Stivers DN, Zhang J, Kim D, Meric-Bernstam F. RNA-binding specificity of Y-box protein 1. RNA Biol 2009; 6: 59-64.
30. Skabkina OV, Lyabin DN, Skabkin MA, Ovchinnikov LP. YB-1 autoregulates translation of its own mRNA at or prior to the step of 40S ribosomal subunit joining. Mol Cell Biol 2005; 25: 3317-3323.
31. Tanaka T, Ohashi S, Funakoshi T, Kobayashi S. YB-1 binds to GluR2 mRNA and CaM1 mRNA in the brain and regulates their translational levels in an activity-dependent manner. Cell Mol Neurobiol 2010; 30: 1089-1100.
32. Evdokimova VM, Kovrigina EA, Nashchekin DV, Davydova EK, Hershey JW, Ovchinnikov LP. The major core protein of messenger ribonucleoprotein particles (p50) promotes initiation of protein biosynthesis in vitro. J Biol Chem 1998; 273: 3574-3581.
33. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol 1999; 9: 1255-1258.
34. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P et al. Temporallycontrolled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. Nucl Acids Res 1999; 27: 4324-4327.
35. Cobbold LC, Spriggs KA, Haines SJ, Dobbyn HC, Hayes C, de Moor CH et al. Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs. Mol Cell Biol 2008; 28: 40-49.
36. Shiota M, Izumi H, Onitsuka T, Miyamoto N, Kashiwagi E, Kidani A et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68: 98-105.